PLX-Immune

**PLX-Immune** is an off-the-shelf, allogeneic placental-derived cell therapy product developed by Pluristem Therapeutics (now Pluri Biotech), consisting of expanded mesenchymal-like adherent stromal cells. It functions by secreting immunomodulatory factors that regulate immune responses, particularly by targeting dendritic cells to inhibit T-cell priming and Th1-driven reactions, enabling use without HLA matching. The therapy has demonstrated potential in modulating inflammation and preventing immune rejection in preclinical and clinical studies, supporting applications in immune-related disorders, though specific indications and development status for PLX-Immune remain limited in available data.